INphoton was founded to provide custom, innovative solutions that accelerate preclinical drug development. The Indiana Center for Biological Microscopy (ICBM) of the Indiana University School of Medicine provides the unique expertise of a diverse group of investigators who have developed state-of-the-art intravital microscopy. The quality of ICBM has been recognized by grants from the National Institutes of Health to establish the George M. O'Brien Center for Advanced Renal Microscopy and Analysis as a national resource for research in renal physiology and pathophysiology. Widespread recognition of the utility of the techniques developed has resulted in increasingly frequent contacts from investigators in biopharma interested in the application of intravital imaging techniques in preclinical drug development.
The INphoton team has conducted studies for the following companies:
|
|
It became apparent that there was a significant market for these services that could not be accommodated within the constraints of academic research. The foundation of INphoton established a commercial entity to provide these services in an efficient and customer-focused fashion. Recruitment of a CEO, Steven R. Plump, MBA and CFO, Brian O'Dea, MBA brought a necessary infusion of proven marketplace expertise.
TESTIMONIALS
"This revolutionary technology potentially has far-reaching consequences on the way of exploring new therapies and conducting preclinical ADME studies my the pharmaceutical/biotech industry. The high-quality data provided by the ICBM has been of significant value to Quark. Professor Molitoris and his team are very cooperative and performed the tasks accurately, on time and within budget. Working with the team was a very pleasant experience."
- Daniel Zurr, CEO, Quark Biotech
"I am a great advocate of what can be learned from these types of studies, and the ability to do this imaging in living, intact systems has provided me with some very important insights into the properties of our molecules. We have worked closely with them in the design of the studies, and I have been impressed with the conduct of the experiments and the consistency of the data we have received between multiple experiments."
- Scott Henry, VP Toxicology, Isis Pharmaceuticals